

## Supplementary Data

SUPPLEMENTARY TABLE S1. DEFINITION OF THE GLYCEMIC VARIABILITY METRICS AND GLUCOSE CONTROL INDICES

### Glucose variability metrics

$SD^{S1}$	$SD = \sqrt{\sum_{i=1}^N (G_i - \bar{G})^2 / (N - 1)}$ <p>where <math>G</math> is glucose reading, <math>N</math> is the number of observations, and <math>I</math> is the sample index</p>
$\%CV^{S1}$	$\%CV = SD / \bar{G} \cdot 100$
$MAGE^{S2}$	$MAGE = \sum_{i=1}^x \lambda_i / x \quad \text{if } \lambda > \nu,$ <p>where <math>\lambda</math> is the blood glucose changes from peak to nadir (or nadir to peak), <math>x</math> is the total number of valid observations, and <math>\nu</math> is 1 SD of mean glucose for a 24-h period</p>
$CONGA_n^{S3}$	$CONGA_n = \sqrt{\sum_{t=1}^k (D_t - \bar{D})^2 / (k - 1)}$ <p><math>D_t = G_t - G_{t-m}</math>, where <math>k</math> is the number of observations where there is an observation <math>nx60</math> min ago, <math>m</math> is <math>nx60</math>, <math>G_t</math> is the glucose reading at time <math>t</math> min after start of observations</p>
$MODD^{S4}$	$MODD = \sum_{t=t_1}^{t_k}  G_t - G_{t-24h}  / k,$ <p>where <math>k</math> is the number of observations with an observation 24 h ago</p>
$M\text{-value}^{S1}$	$M = \sum_{i=1}^N  10 \cdot \log_{10}(G_i / IGV) ^3 / N,$ <p>where <math>G</math> is glucose measured, IGV is the ideal glucose value (default: 100 mg/dL), and <math>N</math> is the total number of readings</p>
$J\text{-index}^{S5}$	$J = 0.001 \cdot (\bar{G} + SD)^2$
$MAG^{S5}$	$MAG = \sum_{i=1}^{N-1} (G_i - G_{i+1}) / T,$ <p>where <math>G_i</math> is the glucose measured, <math>N</math> is the number of measurements, and <math>T</math> is the total time (in hours)</p>
$AARC^{S6}$	$ROC_i = (G(t_i) - G(t_{i+1})) / (t_{i+1} - t_i),$ <p><math>I = 1, 2, 3, \dots, N-1</math>, where <math>G(t_1)</math> and <math>G(t_2)</math> are consecutive glucose readings taken at times <math>t_1</math> and <math>t_2</math>. <math display="block">AARC = \sum_{i=1}^{N-1} ROC_i / (N - 1)</math></p>
$GVP^{S7}$	$GVP = 100 \cdot (L / L_0 - 1),$ $L = \sum_{i=1}^n \sqrt{dx_i^2 + dy_i^2},$ <p>where <math>L_0</math> is the ideal length for a given temporal duration, <math>dx</math> is the decomposition of the temporal line into horizontal component, <math>dy</math> is the decomposition of the temporal line into vertical component, and <math>n</math> is the total number of glucose recordings</p>
$LI^{S8}$	$LI = \sum_{i=1}^{N-1} (G_{i+1} - G_i)^2 / (t_{i+1} - t_i),$ <p>where <math>G</math> is the glucose measured, <math>N</math> is the total number of glucose readings in a week, and <math>t</math> is the time</p>

### Glucose control indexes

$GRADE^{S9}$ $\%GRADE_{\text{hypo}}$	$GRADE = \sum_{i=1}^N \min(50; 425 \cdot \log_{10}(\log_{10}(G_i))) / N,$ $GRADE_{\text{hypo}} = \sum_{i=1}^{N_{\text{hypo}}} \min(50; 425 \cdot \log_{10}(\log_{10}(G_{\text{hypo } i}))) / N_{\text{hypo}},$ $\%GRADE_{\text{hypo}} = GRADE_{\text{hypo}} / GRADE \cdot 100,$ <p>where <math>G</math> is the glucose measured, <math>N</math> is the total number of glucose readings, <math>G_{\text{hypo}}</math> is the glucose value lower than hypoglycemic threshold, <math>N_{\text{hypo}}</math> is the number lower than hypoglycemic threshold glucose readings</p>
$IGC^{S10,S11}$	$IGC = \text{Hypo Index} + \text{Hyper Index},$ $\text{Hypo Index} = \left( \sum_{i=1}^{k_{\text{hypo}}} (LLTR - G_{\text{hypo } i})^b \right) / (N \cdot d),$ $\text{Hyper Index} = \left( \sum_{i=1}^{k_{\text{hyper}}} (G_{\text{hyper } i} - ULTR)^a \right) / (N \cdot c),$ <p>where LLTR is the lower limit of target range (default 80 mg/dL), <math>b</math> is an exponent in the range [1.0–2.0] (default=2.0), <math>d</math> is a scaling factor to weight hypoglycemic and hyperglycemic values (default=30), ULTR is the upper limit of target range (default=140 mg/dL), <math>a</math> is an exponent in the range [1.0–2.0] (default=1.1), and <math>c</math> is a scaling factor (default=30)</p>

(continued)

SUPPLEMENTARY TABLE S1. (CONTINUED)

Glucose control indexes

LBGH HBGH<sup>S12</sup>

$$LBGI = \left( \sum_{i=1}^N rl(x_i) \right) / N,$$

$$HBGI = \left( \sum_{i=1}^N rh(x_i) \right) / N,$$

$$rl(x_i) = 22.77 \cdot f(x_i)^2 \quad \text{if } f(x_i) \leq 0, \text{ and } 0 \text{ otherwise.},$$

$$rh(x_i) = 22.77 \cdot f(x_i)^2 \quad \text{if } f(x_i) > 0, \text{ and } 0 \text{ otherwise.},$$

$$f(x_i) = \ln(x_i)^{1.084} - 5.381,$$

where  $x_i$  is the glucose recording and  $N$  is the total number of recordings

ADRR<sup>S13</sup>

$$ADRR = \left( \sum_{j=1}^M LR^j + HR^j \right) / M,$$

$$LR^j = \max(rl(x_1), \dots, rl(x_n)),$$

$$HR^j = \max(rh(x_1), \dots, rh(x_n)),$$

where  $j$  is the day index,  $M$  is the total number of days,  $x_i$  is the glucose recording, and  $n$  is the total number of recordings per day

PGS<sup>S14</sup>

$$PGS = F(GVP) + F(MG) + F(PTIR) + F(H),$$

$$F(GVP) = 1 + 9 / \left( 1 + e^{-0.049 \cdot (GVP - 65.47)} \right),$$

$$F(MG) = 1 + 9 / \left( 1 + e^{0.1139 \cdot (MG - 72.08)} \right) + 9 / \left( 1 + e^{-0.1139 \cdot (MG - 157.57)} \right),$$

$$F(PTIR) = 1 + 9 / \left( 1 + e^{0.0833 \cdot (PTIR - 55.04)} \right),$$

$$F(H) = F_{54}(H) + F_{70}(H),$$

$$F_{54}(H) = 0.5 + 4.5 \cdot \left( 1 - e^{-0.81093 \cdot N_{54}} \right),$$

$$F_{70}(H) = \begin{cases} 0.5714 \cdot N_{70} + 0.625 & N_{70} \leq 7.65 \\ 5 & N_{70} > 7.65 \end{cases}$$

where MG is the mean glucose, PTIR is the percentage time in range (70–180 mg/dL),  $N_{54}$  is the number of hypoglycemia events per week below the low threshold ( $\leq 54$  mg/dL), and  $N_{70}$  is the number of hypoglycemia events per week below the high threshold ( $\leq 70$  mg/dL)

%CV, coefficient of variation; AARC, average absolute rate of change; ADRR, average daily risk range; CONGAn, continuous overlapping net glycaemic action over an n-hour period; GRADE, glycaemic risk assessment diabetes equation; GVP, glycaemic variability percentage; HBGI, high blood glucose index; IGC, index of glycaemic control; LBGH, low blood glucose index; LI, lability index; MAG, mean absolute glucose; MAGE, mean amplitude of glucose excursion; MODD, mean of daily differences; PGS, personal glycaemic state; SD, standard deviation.

## Supplementary References

- S1. Reddy M, Jugnee N, Anantharaja S, Oliver N: Switching from flash glucose monitoring to continuous glucose monitoring on hypoglycemia in adults with type 1 diabetes at high hypoglycemia risk: the extension phase of the I HART CGM study. *Diabetes Technol Ther* 2018;20:751–757.
- S2. Jaeb Center for Health Research (JCHR)—Diabetes Research Studies. <http://diabetes.jaeb.org/Dataset.aspx>. Accessed June 19, 2019.
- S3. Fabris C, Facchinetti A, Fico G, et al.: Parsimonious description of glucose variability in type 2 diabetes by sparse principal component analysis. *J Diabetes Sci Technol* 2016;10:119–124.
- S4. Aleppo G, Ruedy KJ, Riddlesworth TD, et al.: REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. *Diabetes Care* 2017;40:538–545.
- S5. Hermans MP, Sacks FM, Ahn SA, Rousseau MF: Non-HDL-cholesterol as valid surrogate to apolipoprotein B 100 measurement in diabetes: discriminant Ratio and unbiased equivalence. *Cardiovasc Diabetol* 2011; 10:20.
- S6. Fabris C, Facchinetti A, Sparacino G, et al.: Glucose variability indices in type 1 diabetes: parsimonious set of indices revealed by sparse principal component analysis. *Diabetes Technol Ther* 2014;16:644–652.
- S7. Kovatchev B, Cobelli C: Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. *Diabetes Care* 2016;39:502–510.
- S8. Verkest KR, Fleeman LM, Rand JS, Morton JM: Basal measures of insulin sensitivity and insulin secretion and simplified glucose tolerance tests in dogs. *Domest Anim Endocrinol* 2010;39:194–204.
- S9. McDonnell CM, Donath SM, Vidmar SI, et al.: A novel approach to continuous glucose analysis utilizing glycemic variation. *Diabetes Technol Ther* 2005;7:253–263.
- S10. Danne T, Nimri R, Battelino T, et al.: International consensus on use of continuous glucose monitoring. *Diabetes Care* 2017;40:1631–1640.
- S11. Ryan EA, Shandro T, Green K, et al.: Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. *Diabetes* 2004;53:955–962.
- S12. Hirsch IB, Balo AK, Sayer K, et al.: A simple composite metric for the assessment of glycemic status from continuous glucose monitoring data: implications for clinical practice and the artificial pancreas. *Diabetes Technol Ther* 2017;19(Suppl. 3):S38–S48.
- S13. Whitelaw BC, Choudhary P, Hopkins D: Evaluating rate of change as an index of glycemic variability, using continuous glucose monitoring data. *Diabetes Technol Ther* 2011;13:631–636.
- S14. Wojcicki JM: “J” index. A new proposition of the assessment of current glucose control in diabetic patients. *Horm Metab Res* 1995;27:41–42.